Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

PURPOSE: There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2012
Fag:
Original Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675689/
https://ncbi.nlm.nih.gov/pubmed/22025146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.5040
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker